Literature DB >> 21423852

A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Patricia Kissinger1, Leandro Mena, Judy Levison, Rebecca A Clark, Megan Gatski, Harold Henderson, Norine Schmidt, Susan L Rosenthal, Leann Myers, David H Martin.   

Abstract

OBJECTIVE: To determine if the metronidazole (MTZ) 2-gm single dose (recommended) is as effective as the 7-day 500 mg twice a day dose (alternative) for treatment of Trichomonas vaginalis (TV) among HIV+ women.
METHODS: Phase IV randomized clinical trial; HIV+ women with culture confirmed TV were randomized to treatment arm: MTZ 2-gm single dose or MTZ 500 mg twice a day 7-day dose. All women were given 2-gm MTZ doses to deliver to their sex partners. Women were recultured for TV at a test-of-cure (TOC) visit occurring 6-12 days after treatment completion. TV-negative women at TOC were again recultured at a 3-month visit. Repeat TV infection rates were compared between arms.
RESULTS: Two hundred seventy HIV+/TV+ women were enrolled (mean age = 40 years, ±9.4; 92.2% African American). Treatment arms were similar with respect to age, race, CD4 count, viral load, antiretroviral therapy status, site, and loss-to-follow up. Women in the 7-day arm had lower repeat TV infection rates at TOC [8.5% (11 of 130) versus 16.8% (21 of 125) (relative risk: 0.50, 95% confidence interval = 0.25, 1.00; P < 0.05)] and at 3 months [11.0% (8 of 73) versus 24.1% (19 of 79) (relative risk: 0.46, 95% confidence interval = 0.21, 0.98; P = 0.03)] compared with the single-dose arm.
CONCLUSIONS: The 7-day MTZ dose was more effective than the single dose for the treatment of TV among HIV+ women.

Entities:  

Keywords:  HIV-infected women; Trichomonas vaginalis; metronidazole

Mesh:

Substances:

Year:  2010        PMID: 21423852      PMCID: PMC3058179          DOI: 10.1097/QAI.0b013e3181eda955

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  40 in total

1.  Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole.

Authors:  Jane R Schwebke; Frank J Barrientes
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

2.  Sexually transmitted diseases treatment guidelines, 2006.

Authors:  Kimberly A Workowski; Stuart M Berman
Journal:  MMWR Recomm Rep       Date:  2006-08-04

3.  Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis.

Authors:  Karen A Wendel; Emily J Erbelding; Charlotte A Gaydos; Anne M Rompalo
Journal:  Clin Infect Dis       Date:  2002-08-06       Impact factor: 9.079

Review 4.  Trichomonas vaginalis, HIV, and African-Americans.

Authors:  F Sorvillo; L Smith; P Kerndt; L Ash
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

5.  Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.

Authors:  Patricia Kissinger; W Evan Secor; Jami S Leichliter; Rebecca A Clark; Norine Schmidt; Erink Curtin; David H Martin
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

6.  Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics.

Authors:  Donna J Helms; Debra J Mosure; Carol A Metcalf; John M Douglas; C Kevin Malotte; Sindy M Paul; Thomas A Peterman
Journal:  Sex Transm Dis       Date:  2008-05       Impact factor: 2.830

7.  The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004.

Authors:  Madeline Sutton; Maya Sternberg; Emilia H Koumans; Geraldine McQuillan; Stuart Berman; Lauri Markowitz
Journal:  Clin Infect Dis       Date:  2007-10-15       Impact factor: 9.079

8.  Exposure to alcohol problems and its association with sexual behaviour and biologically confirmed Trichomonas vaginalis among women living with HIV.

Authors:  P Seth; G M Wingood; R J Diclemente
Journal:  Sex Transm Infect       Date:  2008-06-04       Impact factor: 3.519

9.  Frequent douching and clinical outcomes among HIV-infected women.

Authors:  Rebecca A Clark; Katherine P Theall; Angela M Amedee; Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2007-12       Impact factor: 2.830

10.  Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding.

Authors:  Patricia Kissinger; Angela Amedee; Rebecca A Clark; Jeanne Dumestre; Katherine P Theall; Leann Myers; Michael E Hagensee; Thomas A Farley; David H Martin
Journal:  Sex Transm Dis       Date:  2009-01       Impact factor: 2.830

View more
  29 in total

1.  The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women.

Authors:  Megan Gatski; David H Martin; Judy Levison; Leandro Mena; Rebecca A Clark; Mary Murphy; Harold Henderson; Norine Schmidt; Patricia Kissinger
Journal:  Sex Transm Infect       Date:  2011-01-29       Impact factor: 3.519

2.  Sexually transmitted infections and HIV: diagnosis and treatment.

Authors:  Kimberly A Workowski
Journal:  Top Antivir Med       Date:  2012 Apr-May

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 4.  Single-Dose Compared With Multidose Metronidazole for the Treatment of Trichomoniasis in Women: A Meta-Analysis.

Authors:  Katharine Howe; Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2017-01       Impact factor: 2.830

5.  Treatment recommendations for trichomoniasis in women.

Authors:  Patricia Kissinger; Christina A Muzny
Journal:  Lancet Infect Dis       Date:  2019-01       Impact factor: 25.071

6.  Why Does Trichomonas vaginalis Continue to be a "Neglected" Sexually Transmitted Infection?

Authors:  Christina A Muzny
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

7.  Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.

Authors:  Megan Clare Craig-Kuhn; Charleigh Granade; Christina A Muzny; Barbara Van Der Pol; Rebecca Lillis; Stephanie N Taylor; Norine Schmidt; David H Martin; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2019-05       Impact factor: 2.830

8.  Associations between bacterial vaginosis, candida vaginitis, trichomonas vaginalis, and vaginal pathogenic community in Chinese women.

Authors:  Dandan Yuan; Wen Chen; Junjie Qin; Dongqian Shen; Youlin Qiao; Beihua Kong
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

9.  A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.

Authors:  Jennifer E Balkus; Barbra A Richardson; Vernon Mochache; Vrasha Chohan; Jeannie D Chan; Linnet Masese; Juma Shafi; Jeanne Marrazzo; Carey Farquhar; R Scott McClelland
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

10.  Does Antiretroviral Therapy Interfere With the Treatment of Trichomonas vaginalis Among HIV+ Women?

Authors:  Patricia Kissinger; Alys Adamski; Rebecca A Clark; Leandro Mena; Judy Levison; David H Martin
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.